Quest Diagnostics Inc vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while State Street Real Estate Select Sector SPDR ETF trades at $41.58 (market cap $7.61B). The key difference: Quest Diagnostics Inc is far larger — about 3.3× State Street Real Estate Select Sector SPDR ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while State Street Real Estate Select Sector SPDR ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and State Street Real Estate Select Sector SPDR ETF for 75 Days on average.
| DGX | XLRE | |
|---|---|---|
Market Cap | $25.48B | $7.61B |
Volume | 941,866 | 7,876,569 |
Sector | Health | Sector/Thematic |
52-Week High | $247.45 | $46.01 |
52-Week Low | $173.49 | $40.01 |
Typical Hold Time | 56 Days | 75 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
XLRE (Real Estate Select Sector SPDR ETF) trades at $41.515, up 2.33% with a bearish technical bias from moving averages. The ETF focuses on 30 U.S. large-cap real estate holdings with a low 0.08% expense ratio. Recent news highlights competition from global real estate ETFs and sector pressure from rising bond yields, though some analysts see value in REITs for income and diversification.
Outlook: XLRE offers low-cost U.S. real estate exposure but faces headwinds from interest rate volatility and underperformance concerns versus digital infrastructure ETFs. Risks include Fed policy shifts and sector concentration, while opportunities lie in inflation hedging and dividend income. Investor sentiment is mixed amid macro uncertainty.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →